The FDA rejected UCB’s much awaited psoriasis treatment bimekizumab as a result of problems with facility inspections, therefore the firm is now praising the medicine’s potential in a different use. The Belgian pharmaceutical company said on Friday that two phase 3 trials in hidradenitis suppurativa showed “statistically significant and persistent clinically relevant benefits” with respect to placebo.
Related: Calibrate offers weight loss program through medication and counselling
Hidradenitis suppurativa is a chronic and disabling skin condition marked by pus-releasing fistulas, nodules, and abscesses that appear in the armpit, groyne, and buttock regions. In the majority of the investigated nations, it manifests in adolescence and affects 1% of the population. While the pharma company could not bag FDA’s approval, it has surely received European nod.
Read More from FiercePharma
